Clinical Research Directory
Browse clinical research sites, groups, and studies.
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
Sponsor: Eleusis Therapeutics
Summary
A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).
Official title: A Phase I, Randomised, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Intravenous Doses of ELE-101 in Healthy Adult Participants (Part 1) and Part 2, Open-Label Study to Evaluate a Range of Pharmacodynamic Effects of a Single Intravenous Dose of ELE-101 in Patients With Major Depressive Disorder.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2022-10-27
Completion Date
2026-03
Last Updated
2025-02-19
Healthy Volunteers
Yes
Interventions
ELE-101
ELE-101 solution for intravenous infusion
ELE-101 Placebo
ELE-101 placebo matching solution for intravenous infusion
Locations (2)
MAC Clinical Research
Liverpool, United Kingdom
MAC Clinical Research
Manchester, United Kingdom